



LEUKOCARE grants a license on its SPS[®] formulation technology platform to Laboratorios Liomont for development and commercialization of a biosimilar

Biotechnology company LEUKOCARE AG, Germany, and Laboratorios Liomont S.A., Mexico, have entered into a license agreement in the field of biosimilar development. Under the terms of this agreement, Liomont will have access to LEUKOCARE's SPS[®] technology platform and know-how to develop a novel formulation for one of Liomont's pharmaceutical products.

Munich, Germany, June 04, 2018

Munich-based biotechnology company LEUKOCARE has announced today another important milestone in its corporate development by licensing its proprietary Stabilizing and Protecting Solutions (SPS[®]) platform to the Mexican pharmaceutical company Laboratorios Liomont. LEUKOCARE's Stabilizing and Protecting Solutions (SPS[®]) formulation technology platform is used to develop a product-specific formulation for one of Liomont's biosimilars. The application of LEUKOCARE's technologies provides beneficial product features and, moreover, allows Liomont to operate around an existing formulation patent. Liomont plans to enter clinical trials in 2018 and to start commercializing the product by the end of 2019.

Under the terms of this agreement, Liomont gets access to LEUKOCARE's SPS[®] technology platform to develop an undisclosed biosimilar candidate in its pipeline. In return, LEUKOCARE receives royalties on net sales of the product. Details of license and payment terms have not been disclosed by the partners.

Sergio Valentinotti, Director of Life Sciences at Liomont, said, "The development of a formulation providing freedom to operate towards an originator formulation patent is an important milestone for Liomont. Thanks to LEUKOCARE's SPS[®] technologies, we are able to develop a biosimilar and to explore new markets earlier."

Michael Scholl, CEO of LEUKOCARE, added, “We are pleased to support our partner Liomont in developing a novel yet superior formulation. Through this formulation development, it was demonstrated again that our SPS[®] technologies add value to products of partners by providing superior stability and, at the same time, by providing FTO towards existing formulation patents.”

This is LEUKOCARE’s fourth license agreement within 15 months. At the end of 2016, the company entered into a license agreement with US-based vaccine company PaxVax and in February 2017, a strategic alliance with Laupheim-based Rentschler Biopharma SE was established. In April 2018, LEUKOCARE announced a license agreement with Boehringer Ingelheim in the field of animal health.

About LEUKOCARE AG

LEUKOCARE provides a next-generation formulation technology platform for the protection of proteins like biopharmaceuticals to allow the development of better products. The proprietary Stabilizing and Protecting Solutions (SPS[®]) technologies are provided to development projects of partners in the pharmaceutical and medical device industry. LEUKOCARE’s SPS[®] technologies improve stability and quality of biologics like antibodies, vaccines etc. in dry and liquid formulation including high-concentration formulations. SPS[®] technologies also protect proteins in biologically functionalized combination devices.

www.leukocare.com

About Laboratorios Liomont S.A. de C.V

Laboratorios Liomont is a leading Mexican pharmaceutical company that has been in the market for 80 years developing, manufacturing and commercializing Rx and OTC products. More recently, Liomont has invested in the licensing and/or development of several biosimilar monoclonal antibodies that are planned to be commercialized worldwide beginning 2019. As part of its diversification plan, Liomont will open this year a new MAB production facility to supply clinical and commercial material.

Contact:

Michael Scholl

michael.scholl@leukocare.com

+49 (0) 89 7801 6650